Changes in B- and T-lymphocyte and chemokine levels with rituximab treatment in multiple sclerosis

Laura Piccio, Robert T. Naismith, Kathryn Trinkaus, Robyn S. Klein, Becky J. Parks, Jeri A. Lyons, Anne H. Cross

Research output: Contribution to journalArticlepeer-review

178 Scopus citations


Background: B cells are implicated in the pathogenesis of multiple sclerosis. A beneficial effect of B-cell depletion using rituximab has been shown, but the complete mechanism of action for this drug is unclear. Objective: To determine the relationship between T and B cells and changes in cerebrospinal fluid (CSF) chemokine levels with rituximab, a monoclonal antibody that targets CD20. Design: Phase 2 trial of rituximab as an add-on therapy. Setting: The John L. Trotter Multiple Sclerosis Center, Washington University. Participants and Intervention: Thirty subjects who had relapsing-remitting multiple sclerosis with clinical and magnetic resonance imaging activity despite treatment with an immunomodulatory drug received 4 weekly doses of rituximab (375 mg/m2). Main Outcome Measures: Lumbar puncture was performed before and after rituximab infusions in 26 subjects. Levels of B and T lymphocytes in the CSF were enumerated by flow cytometry, and chemoattractant levels were measured by enzyme-linked immunosorbent assay. Results: After rituximab administration, CSF B-cell levels were decreased or undetectable in all subjects, and CSF T-cell levels were reduced in 21 subjects (81%). The mean reduction in CSF cellularity was 95% for B cells and 50% for T cells. After rituximab infusion, CSF CXCL13 and CCL19 levels decreased (P=.002 and P=.03, respectively). The proportional decline in CSF T-cell levels correlated with the proportional decrease in CXCL13 levels (r=0.45; P=.03), suggesting a possible relationship. The CSF IgG index, IgG concentration, and oligoclonal band number were unchanged following treatment. Conclusions: In subjects with multiple sclerosis, B cells are critical for T-cell trafficking into the central nervous system and may alter the process by influencing chemokine production within the central nervous system.

Original languageEnglish
Pages (from-to)707-714
Number of pages8
JournalArchives of neurology
Issue number6
StatePublished - Jun 2010


Dive into the research topics of 'Changes in B- and T-lymphocyte and chemokine levels with rituximab treatment in multiple sclerosis'. Together they form a unique fingerprint.

Cite this